Covalent targeted radioligands potentiate radionuclide therapyXi‐Yang Cui, Zhu Li, Ziren Kong et al.|Nature|2024Cited by 165
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patientsXu Yang, Haitao Zhao, Yiran Li et al.|Hepatology International|2023Cited by 60
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinomaXu Yang, Haitao Zhao, Baofeng Lian et al.|BMC Medicine|2024Cited by 43
Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical studyGuilan Hu, Li Huo, Wenjia Zhu et al.|European Journal of Nuclear Medicine and Molecular Imaging|2022Cited by 39
Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer modelYitian Wu, Li Huo|EJNMMI Radiopharmacy and Chemistry|2024Cited by 22